Background RET rearrangements are targetable, oncogenic lung cancer drivers. While
previous series have shown durable clinical benefit with pemetrexed-based therapies in …

BACKGROUND The discovery of oncogenic drivers has ushered in a new era for lung
cancer, but the role of these mutations in different racial/ethnic minorities has been …

Studies to date have revealed several major molecular alterations that contribute to head
and neck squamous cell carcinoma (HNSCC) initiation, progression, metastatic spread, and …

Lung cancer continues to be the most common cause of cancer-related mortality worldwide.
Recent advances in molecular diagnostics and immunotherapeutics have propelled the …

Background Epidermal growth factor receptor (EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog (KRAS) mutations, and echinoderm microtubule-associated protein-like …

Purpose: To investigate the potential roles that p16 (CDKN2A) and RB activation have in
sensitization to MEK inhibitor in resistant KRAS-mutant non–small cell lung cancer cells …

Several targetable genetic alterations have been found in lung cancer, predominantly in
adenocarcinomas, which have led to important therapeutic advancements with the advent of …

The increasing use of advanced nucleic acid sequencing technologies for clinical
diagnostics and therapeutics has made vital understanding the costs of performing these …

Purpose Recurrent MET exon 14 splicing has been revealed in lung cancers and is a
promising therapeutic target. Because we have limited knowledge about the natural history …

Cancer causes significant morbidity and mortality worldwide, and is the area most targeted
in precision medicine. Recent development of high-throughput methods enables detailed …